Endocrine Abstracts

Background and objectives: Evaluate the impact of therapy with GLP-1 analogues (liraglutide) on glycemic control and weight in patients with type 2 diabetes and poor metabolic control.

Material and methods: We conducted a retrospective observational study analyzing 67 patients with type 2 diabetes mellitus and BMI >30 kg/m², over 6 months of treatment. We evaluated HbA1c and weight at 3 and 6 months, performing statistical analysis with SPSSv18 using the Student’s t-test for paired data.

Results: The mean age was 50.29±13.2 years, being women the 50.7% of them. The average weight at baseline was 17.03±104.26 kg, BMI 38.5±5.99 kg/m² and mean HbA1c 8.4±1.3%. Initially 35.8% used oral antidiabetic monotherapy, 34.3% dual therapy with OAD, 9% triple therapy and the 20.9% remaining were treated with OAD plus insulin. Mean HbA1c at 3 months was 6.7±1.09%, and at 6 months was 6.5±1.2%, evidencing a statistically significant and clinically relevant decrease of mean HbA1c at 3 months of 1.81% (P<0.000) and at 6 months of 1.3% (P<0.000). The average weight at 3 months was 99.2±15.48 kg and at 6 months of 94.18±15.48 kg. We observed a weight loss of 7.46±5.8 kg (P<0.000) after 3 months. At 6 months, there was a weight reduction from baseline of 13.5±16.5 kg (P<0.000). There were mild gastrointestinal secondary effects in six patients that entailed the abandonment of treatment in three cases.

Conclusions: A clinically relevant reduction of HbA1c and weight were observed. The association of liraglutide to conventional diabetes treatment in type 2 diabetic patients with obesity confers a benefit on glycemic control and weight loss.